These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38000933)

  • 1. Significant Survival Differences for Grade Group 4 and Grade Group 5 Prostate Cancer: Detailed Reporting of Pathohistology and Modern Diagnostic Algorithms Are Needed To Tailor Treatment.
    Heidenreich A
    Eur Urol Oncol; 2024 Apr; 7(2):211-212. PubMed ID: 38000933
    [No Abstract]   [Full Text] [Related]  

  • 2. [Modern therapy of prostate cancer].
    Kretschmer A; Stief C; Gratzke C
    MMW Fortschr Med; 2014 Dec; 156(21-22):71-3. PubMed ID: 25608415
    [No Abstract]   [Full Text] [Related]  

  • 3. Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/ml.
    Ito K; Yokomizo A; Tokunaga S; Arai G; Sugimoto M; Akakura K; Hasumi H; Sakai H; Ouraji A; Oki R; Kashiwagi E; Kobori Y; Hirama H; Kitoh H; Uemura H; Hakariya T; Suzuki K;
    J Urol; 2020 Jan; 203(1):83-91. PubMed ID: 31430244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is cancer? A focus on Grade Group 1 prostate cancer.
    Talwar R; Akinsola O; Penson DF
    BJU Int; 2024 Apr; 133(4):360-364. PubMed ID: 38229478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
    Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance.
    Weiner AB; Etzioni R; Eggener SE
    Eur Urol; 2014 Oct; 66(4):611-2. PubMed ID: 24630416
    [No Abstract]   [Full Text] [Related]  

  • 8. Diagnostic challenges of clonal heterogeneity in prostate cancer.
    Haffner MC; De Marzo AM; Yegnasubramanian S; Epstein JI; Carter HB
    J Clin Oncol; 2015 Mar; 33(7):e38-40. PubMed ID: 24638011
    [No Abstract]   [Full Text] [Related]  

  • 9. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.
    Ganz PA; Barry JM; Burke W; Col NF; Corso PS; Dodson E; Hammond ME; Kogan BA; Lynch CF; Newcomer L; Seifter EJ; Tooze JA; Viswanath K; Wessells H
    Ann Intern Med; 2012 Apr; 156(8):591-5. PubMed ID: 22351514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.
    Epstein JI; Zelefsky MJ; Sjoberg DD; Nelson JB; Egevad L; Magi-Galluzzi C; Vickers AJ; Parwani AV; Reuter VE; Fine SW; Eastham JA; Wiklund P; Han M; Reddy CA; Ciezki JP; Nyberg T; Klein EA
    Eur Urol; 2016 Mar; 69(3):428-35. PubMed ID: 26166626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center.
    Carlsson S; Benfante N; Alvim R; Sjoberg DD; Vickers A; Reuter VE; Fine SW; Vargas HA; Wiseman M; Mamoor M; Ehdaie B; Laudone V; Scardino P; Eastham J; Touijer K
    J Urol; 2020 Jun; 203(6):1117-1121. PubMed ID: 31909690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule.
    Vau N; Henriques V; Cheng L; Blanca A; Fonseca J; Montironi R; Cimadamore A; Lopez-Beltran A
    Hum Pathol; 2019 Nov; 93():6-15. PubMed ID: 31442520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: A low prostate-specific antigen predicts a worse outcome in high but not in low/intermediate-grade prostate cancer.
    Ning H; Wu H; Lyu J; Wu F
    Eur J Cancer; 2023 Jul; 187():144-146. PubMed ID: 37163807
    [No Abstract]   [Full Text] [Related]  

  • 14. New prostate cancer grade grouping system predicts survival after radical prostatectomy.
    Erickson A; Sandeman K; Lahdensuo K; Nordling S; Kallajoki M; Seikkula H; Bützow A; Vasarainen H; Boström PJ; Taimen P; Rannikko A; Mirtti T
    Hum Pathol; 2018 May; 75():159-166. PubMed ID: 29447924
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
    Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
    Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gleason Grading, Biochemical Failure, and Prostate Cancer-Specific Death.
    Vollmer RT
    Am J Clin Pathol; 2017 Mar; 147(3):273-277. PubMed ID: 28395050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis prostate cancer: who makes the treatment decision and which treatment is selected? Opinion survey in a prostate cancer patient support group].
    Schnell D; Fiebrandt H; Weissbach L
    Urologe A; 2012 Feb; 51(2):238-41. PubMed ID: 21979906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years.
    Huang H; Muscatelli S; Naslund M; Badiyan SN; Kaiser A; Siddiqui MM
    J Urol; 2019 Jan; 201(1):120-128. PubMed ID: 30059685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prostate cancer histoseminar: Update of the 2016 WHO classification - case No. 8: Acinar prostatic adenocarcinoma, Gleason score 6 (3+3)].
    Ferlicot S
    Ann Pathol; 2017 Jun; 37(3):259-263. PubMed ID: 28522121
    [No Abstract]   [Full Text] [Related]  

  • 20. When is prostate cancer really cancer?
    Berman DM; Epstein JI
    Urol Clin North Am; 2014 May; 41(2):339-46. PubMed ID: 24725494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.